Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-23-034480
Filing Date
2023-09-28
Accepted
2023-09-28 06:06:03
Documents
53
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 990061
2 ex10-10.htm EX-10.10 20987
3 ex31-1.htm EX-31.1 18066
4 ex31-2.htm EX-31.2 17986
5 ex32-1.htm EX-32.1 4252
6 ex32-2.htm EX-32.2 4282
7 form10-k_001.jpg GRAPHIC 5791
  Complete submission text file 0001493152-23-034480.txt   3991119

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE nxen-20230630.xsd EX-101.SCH 30424
9 XBRL CALCULATION FILE nxen-20230630_cal.xml EX-101.CAL 33681
10 XBRL DEFINITION FILE nxen-20230630_def.xml EX-101.DEF 128882
11 XBRL LABEL FILE nxen-20230630_lab.xml EX-101.LAB 262765
12 XBRL PRESENTATION FILE nxen-20230630_pre.xml EX-101.PRE 206607
47 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 411360
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-K | Act: 34 | File No.: 000-55320 | Film No.: 231286062
SIC: 2834 Pharmaceutical Preparations